The US Food and Drug Administration (USFDA) has issued five observations on the Active Pharmaceutical Ingredients (APIs) plant of Dr Reddy’s Laboratories Ltd, located at Srikakulam, Andhra Pradesh.
“The audit of our API manufacturing plant at Srikakulum, Andhra Pradesh (CTO VI) by the USFDA has been completed on January 28, 2020. We have been issued a Form 483 with five observations,” the Hyderabad-based pharmaceutical firm said in an intimation of the bourses. “We will address them comprehensively within the stipulated timeline.”
The Dr Reddy’s scrip remained mostly stable on Wednesday. It gained 0.07 per cent over the previous close on the BSE to trade at ₹3,191 intraday.
Published on January 29, 2020
Companies to follow
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.